The hardest part of adoption? There is none.
OTX-PP01 is applied during a routine dressing change. Same steps. Same workflow. Same hands. No retraining. No new equipment. Apply. Carry on with routine tasks. Remove. The medicine does the rest.
50 million people live with wounds that won't heal. The best medicine can offer them is a sponge. We are building the pharmaceutical platform that wound care has always needed.
To bring pharmaceutical medicine to wound care — turning a market built on management into one built on healing.
The 5-year mortality rate for an unhealed diabetic foot ulcer is around 30% — rivalling many forms of cancer. Every 20 seconds, someone loses a limb to amputation. Yet the best available tools remain absorbent dressings — sponges — that manage symptoms without treating the underlying pathology. No amount of iteration on a sponge will produce a pharmaceutical outcome.
New drugs approved for cancer
in the last 25 years
FDA-approved wound healing
therapeutics in the same period
The NIH spends ~15% of its budget on cancer research — roughly $7.6 billion a year. It spends approximately 0.1% on wound healing — around $30 million. A 240:1 funding ratio, for a condition with comparable mortality.
Of total global wound care spending, 90% is consumed by labour — endless nurse visits and dressing changes. Only 6% goes to products. The entire commercial model is built around devices that manage wounds. No one has built the pharmaceutical that heals them.
The wound care cost structure is dominated by clinical labour. A treatment that accelerates healing eliminates visits — not just dressings.
Wound care consumes up to 7% of healthcare expenditure in developed nations. The economic case for treatment over management is overwhelming.
No approved drug treats the underlying pathophysiology of chronic wounds. This remains a device market in a problem that requires a pharmaceutical solution.
A grandmother who hasn't walked unaided in two years. A veteran whose injury never closed. A diabetic patient facing amputation — not because medicine can't help, but because no medicine exists. These are the people we are building ONYA for.
Chronic wounds affect over 50 million people worldwide. Most will never receive a pharmaceutical treatment — because until now, there hasn't been one.
We are introducing an entirely new therapeutic category, and we're calling it Active Exudate Therapy (AET). AET is the medicinal modulation of wound exudate at the source. OTX-PP01 combines a well-characterised active compound — with over 150 years of safe clinical use — with a patented, stabilised patch delivery system. It takes 5–15 minutes to apply, requires zero incremental nurse time, and integrates seamlessly into existing clinical workflows.
Astringent action reduces excessive wound fluid production at the source, breaking the self-perpetuating inflammatory cycle that stalls healing.
Broad-spectrum antimicrobial eliminates bacteria, fungi, and viruses through oxidation — a mechanism to which organisms cannot develop resistance.
Creates the wound environment necessary for the body's regenerative processes to resume. Visits space out from daily to weekly. The patient gets their life back.
OTX-PP01 doesn't just work for patients. It aligns incentives across the entire healthcare ecosystem — clinicians, payers, and the people who matter most.
The hardest part of adoption? There is none.
OTX-PP01 is applied during a routine dressing change. Same steps. Same workflow. Same hands. No retraining. No new equipment. Apply. Carry on with routine tasks. Remove. The medicine does the rest.
District nurses in the UK spend up to 50% of their time on wound care — most of it changing dressings on wounds that aren't healing. OTX-PP01 doesn't just treat the patient. It frees the clinician, reduces the burden on health systems, and redirects care where it's needed most.
ONYA's patented platform stabilises and delivers a well-characterised active pharmaceutical ingredient via a silicone-based patch. The same core technology, shared manufacturing process, and common regulatory framework extend across multiple high-value indications. Future pipeline assets leverage clinical data generated by the lead programme — reducing incremental risk and development cost.
First-in-class medicated patch for diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Seamless Phase 2/3 adaptive trial design approved by the MHRA. Phase 1 waived due to established safety profile. FDA 505(b)(2) pathway confirmed.
72-hour wound stabilisation for battlefield and field trauma. The widespread use of drones has created drone-denied airspace, ending the Golden Hour and delaying casualty evacuation for 24–72 hours. A strategic necessity for modern defence medicine.
Malignant fungating wounds in advanced cancer patients. Controls heavy exudate and eliminates the bacteria responsible for severe malodour. No approved pharmacological treatments exist.
Platform extensibility into large adjacent markets. Same core technology and shared manufacturing. Future assets leverage clinical data from the lead programme — zero incremental risk, massive optionality.
Our active molecule has an established safety profile — 150+ years of clinical use and 80+ years of formal pharmacological data. This compresses the traditional biotech development timeline dramatically.
MHRA confirmed: the established safety record of the active compound — with over 150 years of documented clinical use — eliminates the requirement for a healthy volunteer study. Direct to patient trials.
The FDA's accelerated route for reformulated known molecules. Leverages existing clinical data to substantially reduce the pre-clinical and regulatory burden.
Combined Phase 2/3 trial approved by the MHRA. Maximises capital efficiency and compresses the timeline to topline results.
Core patent portfolio granted across 30+ countries including the US, 17 European states, China, Japan, Australia, India, and South Korea. Multi-layered protection through 2041+.
The widespread use of drones has ended the Golden Hour. Casualties now wait 24–72 hours for evacuation through drone-denied airspace. A 72-hour wound stabilisation system is not an incremental improvement — it is a strategic necessity.
OTX-PP02 is a field-deployable version of ONYA's core platform, engineered for sustained antimicrobial and astringent action in austere environments. It is designed to stabilise wounds, prevent infection — including antibiotic-resistant strains — and preserve tissue until surgical intervention is possible.
Linear release profile maintains antimicrobial and astringent action over a full 72 hours — bridging the gap between injury and surgical care.
Perforated top layer allows imaging without dressing removal in field hospitals and forward surgical teams.
Shelf-stable formulation engineered for austere environments. No refrigeration, no reconstitution, no specialist training required.
Effective against bacteria, fungi, and viruses — including MRSA and antibiotic-resistant strains — through oxidative action to which organisms cannot develop resistance.
A young athlete with a surgical wound that won't close. A veteran whose combat injury never healed. A cancer patient with a fungating wound that robs them of dignity. Chronic wounds cut across age, background, and circumstance — and until now, none of them had a pharmaceutical treatment.
Chronic wounds affect over 40 million people worldwide — across every age group, every demographic, every healthcare system.
The combination that turns conviction into cures.
Ebbw Vale, UK — ONYA Therapeutics, a clinical-stage company developing first-in-class pharmaceutical treatments for chronic and acute wounds, today announced the successful close of a £2.6 million seed financing round.
The round was backed by the company's founders and team members, UK angel investors led by South East Angels, and investors from the US and continental Europe. Proceeds will fund the company through its Series A raise and into clinical development of OTX-PP01.
"This seed round reflects genuine conviction from people who have examined our science, our team, and our regulatory pathway in detail," said Thomas Hafner, CEO and Founder of ONYA Therapeutics. "We are building the first pharmaceutical company to treat chronic wounds — not manage them. The support from investors across three continents gives us the runway and the mandate to execute on our Series A and move OTX-PP01 into the clinic."
Ebbw Vale, UK — ONYA Therapeutics today announced the appointment of Professor Steven Jeffery as Chair of its Scientific Advisory Board. A distinguished consultant plastic surgeon with a decorated military career, Professor Jeffery brings unparalleled expertise in trauma, burns, and advanced wound management.
Professor Jeffery's career includes service in the Royal Army Medical Corps with operational tours in Northern Ireland, Afghanistan, and elsewhere. He is an expert adviser to the NICE Medical Technologies Evaluation Programme and an Internal Clinician at BSI.
"Steve is one of a very small number of people in the world who has treated the full spectrum of wound complexity — from battlefield trauma to chronic non-healing wounds in ageing populations," said Thomas Hafner, CEO. "His appointment signals the seriousness of our clinical ambition and the calibre of leadership we are assembling."
"The company's approach to wound care is scientifically robust and has the potential to address significant unmet needs I've witnessed firsthand throughout my career," said Professor Jeffery. "I look forward to helping guide the development of a platform that could make a real difference for both patients and clinicians."
We are building the company that transforms wound care into wound healing.
If you are a clinician, researcher, industry partner, or investor — we want to hear from you.
ONYA Therapeutics Limited
The Innovation Centre, Festival Drive
Ebbw Vale NP23 8XA, United Kingdom